Storm Therapeutics, a Cambridge, UK-based cancer drug development company, secured £12m in Series A funding.
Backers included Imperial Innovations, Cambridge Innovation Capital, Merck Ventures and Pfizer Venture Investments.
The company will use the proceeds of the funding to identify small molecule modulators of these novel targets in RNA modification pathways and develop them into new classes of anti-cancer treatments.
A spin-out company from the University of Cambridge’s Gurdon Institute, and based upon the work of its founders Professor Tony Kouzarides and Professor Eric Miska in the field of RNA epigenetics, Storm Therapeutics focuses on the identification and development of small molecule drugs that target RNA-modifying enzymes. RNA (ribonucleic acid) is the template of all protein synthesis and has key regulatory functions in the cell. There is growing understanding of the importance of RNA modification in the development of cancer, opening up novel therapeutic targets in cancer treatment.